CRC_PCYC 1134 M

informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia

The purpose of the Inform CLL is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors and other approved anti-CLL therapies/regimens. This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported HRQoL.

Key Inclusion Criteria:

• Initiating treatment within ± 30 days of enrollment

• Availability of documentation on previous CLL/SLL treatment and duration of response in the patient’s medical records
N/A
NCT02582879
Cancer
Hematologic
Peter Jiang, M.D., Ph.D.
Pharmacyclics
Heather Sights
  • Providence Regional Cancer Partnership - Everett